CKAP4, a DKK1 receptor, is a biomarker in exosomes derived from pancreatic cancer and a molecular target for therapy

Purpose: The survival rate of pancreatic ductal adenocarcinoma (PDAC) is poor, thus novel molecularly targeted therapy and companion diagnostics are required. We asked whether cytoskeleton-associated protein 4 (CKAP4), a novel Dickkopf1 (DKK1) receptor, is a candidate for PDAC diagnosis and therapy. Experimental Design:Whether CKAP4 can be secreted with small extracellular vesicles (SEVs) from PDAC cells was examined. It was also investigated whether CKAP4 can be detected in sera from PDAC patients by enzyme-linked immuno-sorbent assay (ELISA) using newly generated anti-CKAP4 monoclonal antibodies (mAbs) and whether anti-CKAP4 mAbs can show anti-tumor activity in vivo. Results:CKAP4 was secreted with SEVs from PDAC cells, and the SEVs exhibited the characteristics of exosomes. The secretion of CKAP4-containing exosomes was mediated by DKK1-dependent endocytosis routes and required exosome biogenesis molecules. Two ELISAs capable of detecting tumor-secreted CKAP4 were developed. The serum CKAP4 levels were higher in PDAC patients than healthy control individuals. CKAP4 was highly detected in the sera of pancreatic tumor-bearing xenografted mice and PDAC patients, whereas CKAP4 was barely detectable in sera from normal mice and post-operative patients. Anti-CKAP4 mAbs with different epitopes demonstrated the inhibitory activities for the binding of DKK1 and CKAP4, AKT activity, and proliferation and migration of PDAC cells. Anti-CKAP4 mAbs also suppressed xenograft tumor formation in immunodeficient mice and extended the survival of mice receiving intraperitoneal or orthotopic injection of PDAC cells. Conclusions:CKAP4 secreted in exosomes may represent a biomarker for PDAC. Anti-CKAP4 mAbs can contribute to the development of novel diagnostic methods and therapeutics.

http://bit.ly/2CPVMpj